A Phase 2 interventional study of Deucravacitinib and Placebo in Lupus Erythematosus, Discoid and Lupus Erythematosus, Subacute Cutaneous, sponsored by Bristol-Myers Squibb. Active, not recruiting at 41 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Lupus Erythematosus, Discoid with a site in United States — 5 open to participants now, 10 under way, 7 of them phase 3. Lupus Erythematosus, Discoid · United States.
Among the 31 studies in Lupus Erythematosus, Discoid with a site in United States, this one is the 10th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2021, is one of 14 in phase 2, and was the 18th registered.
42 studies on the registry are indexed under Lupus Erythematosus, Discoid; 7 are open to participants now.
Browse Lupus Erythematosus, Discoid studies →5 of the 31 studies in Lupus Erythematosus, Discoid with a site in United States are open now. Recruiting first, the newest first:
Beeline Medicines Corporation · Sites in United States
Ages 16+
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
Biogen · Sites in United States, Argentina, Brazil and 22 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Lupus Erythematosus, Discoid studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 7
First in 1997; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 45 across 33 interventional studies indexed under Lupus Erythematosus, Discoid.
Median enrollment 48 across the 27 interventional studies, 33 across the 4 observational. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 31 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 3 studies filed under Lupus Erythematosus, Discoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 31 studies in Lupus Erythematosus, Discoid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, efficacy, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE). This study will also assess if deucravacitinib is biologically active and potentially effective in the treatment of participants with moderate to severe DLE/SCLE with or without systemic lupus erythematosus (SLE) that is not well controlled with standard of care therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Deucravacitinib
Drug: Deucravacitinib
Drug: Placebo
Specified dose on specified days
Specified dose on specified days
Percentage Change From Baseline in CLASI Activity Score at Week 16
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70
Time frame: From first dose to Week 16 (approximately 16 weeks)
Percentage of Participants With an Improvement of ≥ 50% From Baseline in the CLASI-A Score (CLASI-50).
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70
Time frame: From first dose to Week 16 (approximately 16 weeks)
Percentage of Participants Who Have Disease Improvement as Defined by a Reduction in CLASI-A of ≥ 4 Points From Baseline.
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70
Time frame: From first dose to Week 16 (approximately 16 weeks)
Mean Change From Baseline in CLASI-A Score.
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70
Time frame: From first dose to Week 16 (approximately 16 weeks)
Percentage of Participants Who Have a Complete Response (CR) on CLASI-A Defined as a Score of "0".
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70 Complete Response (CR) on CLASI-A defined as a score of "0".
Time frame: From first dose to Week 16 (approximately 16 weeks)
Number of Participants With Safety Related Events in the Placebo Controlled Period
Number of participants with safety related events in the placebo controlled period
Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Number of Participants With Safety Related Events in the Active Treatment Period
Number of participants with safety related events in the active treatment period
Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Number of Participants With Clinically Significant Laboratory Abnormalities in the Placebo Controlled Period
Number of participants with clinically significant laboratory abnormalities in the placebo controlled period
Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Number of Participants With Clinically Significant Laboratory Abnormalities in the Active Treatment Period
Number of participants with clinically significant laboratory abnormalities in the active treatment period
Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Number of Participants With Clinically Significant Vital Sign Abnormalities in the Placebo Controlled Period
Number of participants with clinically significant vital sign abnormalities in the placebo controlled period
Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Number of Participants With Clinically Significant Vital Sign Abnormalities in the Active Treatment Period
Number of participants with clinically significant vital sign abnormalities in the active treatment period
Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Number of Participants With Clinically Significant ECG Abnormalities in the Placebo Controlled Period
Number of participants with clinically significant ECG abnormalities in the placebo controlled period
Time frame: From signing informed consent to end of active treatment period (Approximately 56 weeks)
Number of Participants With Clinically Significant ECG Abnormalities in the Active Treatment Period
Number of participants with clinically significant ECG abnormalities in the active treatment period
Time frame: From signing informed consent to end of active treatment period (Approximately 56 weeks)
| Milestone | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo | Active-Treatment Period: Treatment 1 | Active-Treatment Period: Treatment 2 |
|---|---|---|---|---|---|
| Started | 25 | 25 | 24 | 0 | 0 |
| Completed | 21 | 20 | 22 | 0 | 0 |
| Not completed | 4 | 5 | 2 | 0 | 0 |
| Withdrew: Request to discontinue | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 1 | 1 | 2 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Ongoing study period | 0 | 1 | 0 | 0 | 0 |
| Milestone | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo | Active-Treatment Period: Treatment 1 | Active-Treatment Period: Treatment 2 |
|---|---|---|---|---|---|
| Started | 16 | 20 | 0 | 9 | 9 |
| Completed | 11 | 9 | 0 | 5 | 6 |
| Not completed | 5 | 11 | 0 | 4 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Request to discontinue | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Administrative reason by sponsor | 1 | 5 | 0 | 2 | 2 |
| Withdrew: Other reasons | 1 | 1 | 0 | 0 | 1 |
| Withdrew: Ongoing study period | 2 | 4 | 0 | 1 | 0 |
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70
| Percentage change from baseline | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo |
|---|---|---|---|
| Percentage Change From Baseline in CLASI Activity Score at Week 16 | -48.56 ± 44.684 | -48.93 ± 33.302 | -27.31 ± 29.716 |
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70
| Percentage of participants | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo |
|---|---|---|---|
| Percentage of Participants With an Improvement of ≥ 50% From Baseline in the CLASI-A Score (CLASI-50). | 60.0 | 54.2 | 21.7 |
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70
| Percentage of participants | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo |
|---|---|---|---|
| Percentage of Participants Who Have Disease Improvement as Defined by a Reduction in CLASI-A of ≥ 4 Points From Baseline. | 60.0 | 66.7 | 39.1 |
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70
| Score on a Scale | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo |
|---|---|---|---|
| Mean Change From Baseline in CLASI-A Score. | -9.8 ± 12.69 | -7.5 ± 5.92 | -4.3 ± 5.54 |
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70 Complete Response (CR) on CLASI-A defined as a score of "0".
| Percentage of Participants | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo |
|---|---|---|---|
| Percentage of Participants Who Have a Complete Response (CR) on CLASI-A Defined as a Score of "0". | 12.0 | 4.2 | 0 |
Number of participants with safety related events in the placebo controlled period
| Participants | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo |
|---|---|---|---|
| TEAE | 17 | 19 | 12 |
| Treatment-related TEAEs | 11 | 11 | 3 |
| Serious TEAE | 2 | 2 | 1 |
| Treatment related Serious TEAE | 1 | 1 | 0 |
Number of participants with safety related events in the active treatment period
| Participants | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Active-Treatment Period: Treatment 1 | Active-Treatment Period: Treatment 2 |
|---|---|---|---|---|
| TEAEs | 11 | 10 | 5 | 6 |
| Treatment related TEAEs | 5 | 5 | 2 | 2 |
| Serious TEAEs | 1 | 0 | 0 | 1 |
| Treatment related serious TEAE | 1 | 0 | 0 | 0 |
Number of participants with clinically significant laboratory abnormalities in the placebo controlled period
| Participants | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo |
|---|---|---|---|
| Creatinine Kinase ≥ 2.5x ULN | 1 | 1 | 2 |
| Hemoglobin < 9 g/dL (90g/L) | 1 | 0 | 0 |
Number of participants with clinically significant laboratory abnormalities in the active treatment period
| Participants | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Active-Treatment Period: Treatment 1 | Active-Treatment Period: Treatment 2 |
|---|---|---|---|---|
| ALT > 3xULN | 0 | 0 | 1 | 0 |
| AST > 3xULN | 0 | 0 | 1 | 0 |
| Creatinine Kinase ≥ 2.5x ULN | 3 | 1 | 2 | 1 |
| Hemoglobin < 9 g/dL (90g/L) | 1 | 0 | 0 | 0 |
Number of participants with clinically significant vital sign abnormalities in the placebo controlled period
| Participants | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo |
|---|---|---|---|
| Number of Participants With Clinically Significant Vital Sign Abnormalities in the Placebo Controlled Period | 0 | 0 | 0 |
Number of participants with clinically significant vital sign abnormalities in the active treatment period
| Participants | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Active-Treatment Period: Treatment 1 | Active-Treatment Period: Treatment 2 |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Vital Sign Abnormalities in the Active Treatment Period | 0 | 0 | 0 | 0 |
Number of participants with clinically significant ECG abnormalities in the placebo controlled period
| Participants | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo |
|---|---|---|---|
| Number of Participants With Clinically Significant ECG Abnormalities in the Placebo Controlled Period | 0 | 0 | 0 |
Number of participants with clinically significant ECG abnormalities in the active treatment period
| Participants | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Active-Treatment Period: Treatment 1 | Active-Treatment Period: Treatment 2 |
|---|---|---|---|---|
| Number of Participants With Clinically Significant ECG Abnormalities in the Active Treatment Period | 0 | 0 | 0 | 0 |
Collected over AEs/SAEs are collected from the time of signing the consent until post treatment follow up period of 28 days, approximately 13 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-Controlled Period - DEUC 3 mg BID | 0/25 (0%) | 2/25 (8%) | 15/25 (60%) |
| Placebo-Controlled Period - DEUC 6 mg BID | 0/24 (0%) | 2/24 (8.3%) | 15/24 (62.5%) |
| Placebo-Controlled Period - Placebo BID | 0/24 (0%) | 1/24 (4.2%) | 8/24 (33.3%) |
| Active Treatment Period - DEUC 3 mg BID | 0/16 (0%) | 1/16 (6.3%) | 11/16 (68.8%) |
| Active Treatment Period - DEUC 6 mg BID | 0/20 (0%) | 0/20 (0%) | 10/20 (50%) |
| Active Treatment Period - Placebo-DEUC 3 mg BID | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| Active Treatment Period - Placebo-DEUC 6 mg BID | 0/9 (0%) | 1/9 (11.1%) | 6/9 (66.7%) |
| Event | Placebo-Controlled Period - DEUC 3 mg BID | Placebo-Controlled Period - DEUC 6 mg BID | Placebo-Controlled Period - Placebo BID | Active Treatment Period - DEUC 3 mg BID | Active Treatment Period - DEUC 6 mg BID | Active Treatment Period - Placebo-DEUC 3 mg BID | Active Treatment Period - Placebo-DEUC 6 mg BID |
|---|---|---|---|---|---|---|---|
| Humerus fractureInjury, poisoning and procedural complications | 0/25 | 0/24 | 0/24 | 0/16 | 0/20 | 0/9 | 1/9 |
| COVID-19Infections and infestations | 0/25 | 0/24 | 0/24 | 1/16 | 0/20 | 0/9 | 0/9 |
| PyrexiaGeneral disorders | 0/25 | 1/24 | 0/24 | 0/16 | 0/20 | 0/9 | 0/9 |
| PneumoniaInfections and infestations | 0/25 | 1/24 | 0/24 | 0/16 | 0/20 | 0/9 | 0/9 |
| Stress urinary incontinenceRenal and urinary disorders | 0/25 | 0/24 | 1/24 | 0/16 | 0/20 | 0/9 | 0/9 |
| Oral herpesInfections and infestations | 1/25 | 0/24 | 0/24 | 0/16 | 0/20 | 0/9 | 0/9 |
| Abortion induced incompleteInjury, poisoning and procedural complications | 1/25 | 0/24 | 0/24 | 0/16 | 0/20 | 0/9 | 0/9 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/25 | 0/24 | 0/24 | 0/16 | 0/20 | 0/9 | 0/9 |
| Event | Placebo-Controlled Period - DEUC 3 mg BID | Placebo-Controlled Period - DEUC 6 mg BID | Placebo-Controlled Period - Placebo BID | Active Treatment Period - DEUC 3 mg BID | Active Treatment Period - DEUC 6 mg BID | Active Treatment Period - Placebo-DEUC 3 mg BID | Active Treatment Period - Placebo-DEUC 6 mg BID |
|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 1/25 | 1/24 | 0/24 | 5/16 | 1/20 | 2/9 | 0/9 |
| LeukopeniaBlood and lymphatic system disorders | 0/9 | 1/4 | 0/6 | 0/16 | 0/20 | 0/9 | 0/9 |
| PalpitationsCardiac disorders | 0/9 | 1/4 | 1/6 | 0/16 | 0/20 | 0/9 | 0/9 |
| Eyelid oedemaEye disorders | 0/9 | 1/4 | 0/6 | 0/16 | 0/20 | 0/9 | 0/9 |
| Oral mucosa erosionGastrointestinal disorders | 0/9 | 1/4 | 0/6 | 0/16 | 0/20 | 0/9 | 0/9 |
| Oral painGastrointestinal disorders | 0/9 | 1/4 | 0/6 | 0/16 | 0/20 | 0/9 | 0/9 |
| FatigueGeneral disorders | 0/9 | 1/4 | 0/6 | 0/16 | 0/20 | 0/9 | 0/9 |
| BacteraemiaInfections and infestations | 0/9 | 1/4 | 0/6 | 0/16 | 0/20 | 0/9 | 0/9 |
| TendonitisMusculoskeletal and connective tissue disorders | 0/9 | 1/4 | 0/6 | 0/16 | 0/20 | 0/9 | 0/9 |
| Seborrhoeic keratosisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/9 | 1/4 | 0/6 | 0/16 | 0/20 | 0/9 | 0/9 |
| Age, Categorical(Participants) | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 22 | 25 | 21 | 68 |
| >=65 years | 3 | 0 | 3 | 6 |
| Age, Continuous(Years) | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo | Total |
|---|---|---|---|---|
| Mean | 47.3 ± 15.06 | 42.8 ± 12.16 | 46.2 ± 12.82 | 45.4 ± 13.36 |
| Sex: Female, Male(Participants) | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo | Total |
|---|---|---|---|---|
| Female | 17 | 19 | 18 | 54 |
| Male | 8 | 6 | 6 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 5 | 13 | 27 |
| Not Hispanic or Latino | 16 | 20 | 11 | 47 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo-Controlled Period: Treatment 1 | Placebo-Controlled Period: Treatment 2 | Placebo-Controlled Period: Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 3 | 4 |
| Asian | 2 | 3 | 2 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 6 | 2 | 12 |
| White | 17 | 13 | 13 | 43 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 3 | 4 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2021 to primary completion in Aug 2024, 37 months.
Results were first posted in Sep 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib
Lupus Erythematosus, Discoid →